NCT00545467View on ClinicalTrials.gov

Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents

PHASE4CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

July 31, 2009

Conditions
DSM-IV SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Aripiprazole

Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.

Trial Locations (1)

100

Department of Psychiatry, National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

collaborator

Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan

OTHER_GOV

lead

National Taiwan University Hospital

OTHER

NCT00545467 - Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents | Biotech Hunter | Biotech Hunter